The study will use the Dexcom G7 Continuous Glucose Monitoring system, developed by a global leader in CGM technology, to assess whether continuous monitoring can improve blood sugar control when integrated into a structured, multidisciplinary care programme.
Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.